DR5 Antibody - #DF6368

>>买2送1 进行中>>
>>赠JD卡 进行中>>
(3)   (6)  
产品: DR5 抗体
货号: DF6368
描述: Rabbit polyclonal antibody to DR5
应用: WB IHC
文献验证: WB
反应: Human
分子量: 48kDa; 48kD(Calculated).
蛋白号: O14763
RRID: AB_2838332

浏览相似产品>>

   规格 价格 库存
 50ul RMB¥ 1250 现货
 100ul RMB¥ 2300 现货
 200ul RMB¥ 3000 现货

货期: 当天发货

联系销售
相关下载
MSDS
说明书
COA
实验方案
WB Handbook
IHC Protocol
IF/ICC Protocol

产品描述

来源:
Rabbit
应用:
WB 1:500-1:2000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:
Human
克隆:
Polyclonal
特异性:
DR5 Antibody detects endogenous levels of total DR5.
RRID:
AB_2838332
引用格式: Affinity Biosciences Cat# DF6368, RRID:AB_2838332.
偶联:
Unconjugated.
纯化:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
别名:

展开/折叠

Fas like protein; Apoptosis inducing protein TRICK2A/2B; Apoptosis inducing receptor TRAIL R2; CD262; CD262 antigen; Cytotoxic TRAIL receptor 2; Death domain containing receptor for TRAIL/Apo 2L; Death receptor 5; DR5; KILLER; KILLER/DR5; OTTHUMP00000123492; OTTHUMP00000123493; p53 regulated DNA damage inducible cell death receptor(killer); TNF related apoptosis inducing ligand receptor 2; TNF-related apoptosis-inducing ligand receptor 2; TNFRSF10B; TR10B_HUMAN; TRAIL R2; TRAIL receptor 2; TRAIL-R2; TRAILR2; TRICK2; TRICK2A; TRICK2B; TRICKB; Tumor necrosis factor receptor like protein ZTNFR9; Tumor necrosis factor receptor superfamily member 10B; Tumor necrosis factor receptor superfamily, member 10b; ZTNFR9;

抗原和靶标

免疫原:

A synthesized peptide derived from human DR5, corresponding to a region within N-terminal amino acids.

Uniprot:

O14763(TR10B_HUMAN) >>Visit HPA database.

基因/基因ID:
TNFRSF10B(8795)
表达:
O14763 TR10B_HUMAN:

Widely expressed in adult and fetal tissues; very highly expressed in tumor cell lines such as HeLaS3, K-562, HL-60, SW480, A-549 and G-361; highly expressed in heart, peripheral blood lymphocytes, liver, pancreas, spleen, thymus, prostate, ovary, uterus, placenta, testis, esophagus, stomach and throughout the intestinal tract; not detectable in brain.

描述:
The tumor necrosis factor receptor family, which includes TNF-RI, Fas, DR3, DR4, DR5, and DR6, plays an important role in the regulation of apoptosis in various physiological systems (1,2). The receptors are activated by a family of cytokines that include TNF, FasL, and TRAIL. They are characterized by a highly conserved extracellular region containing cysteine-rich repeats and a conserved intracellular region of about 80 amino acids termed the death domain (DD). The DD is important for transducing the death signal by recruiting other DD containing adaptor proteins (FADD, TRADD, RIP) to the death-inducing signaling complex (DISC), resulting in activation of caspases. DR5 is a receptor for TNF-related apoptosis inducing ligand (TRAIL), which has been been shown to induce apoptosis in variety of cell types and has been targeted for cancer therapy (1-5). Structurally, DR5 contains an amino-terminal leader cleavage site followed by an extracellular region containing two cysteine-rich repeats, then a central transmembrane domain and a carboxy-terminal death domain. DR5 is expressed in a wide variety of tissues and is transcriptional target for p53 (6-8). It induces apoptosis through a FADD-dependent pathway. Deletion of DR5 leads to resistance in TRAIL-mediated apoptosis as well as an abrogated response to DNA-damaging stimuli (9).
序列:
MEQRGQNAPAASGARKRHGPGPREARGARPGPRVPKTLVLVVAAVLLLVSAESALITQQDLAPQQRAAPQQKRSSPSEGLCPPGHHISEDGRDCISCKYGQDYSTHWNDLLFCLRCTRCDSGEVELSPCTTTRNTVCQCEEGTFREEDSPEMCRKCRTGCPRGMVKVGDCTPWSDIECVHKESGTKHSGEVPAVEETVTSSPGTPASPCSLSGIIIGVTVAAVVLIVAVFVCKSLLWKKVLPYLKGICSGGGGDPERVDRSSQRPGAEDNVLNEIVSILQPTQVPEQEMEVQEPAEPTGVNMLSPGESEHLLEPAEAERSQRRRLLVPANEGDPTETLRQCFDDFADLVPFDSWEPLMRKLGLMDNEIKVAKAEAAGHRDTLYTMLIKWVNKTGRDASVHTLLDALETLGERLAKQKIEDHLLSSGKFMYLEGNADSAMS

研究背景

功能:

Receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-kappa-B. Essential for ER stress-induced apoptosis.

细胞定位:

Membrane>Single-pass type I membrane protein.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
组织特异性:

Widely expressed in adult and fetal tissues; very highly expressed in tumor cell lines such as HeLaS3, K-562, HL-60, SW480, A-549 and G-361; highly expressed in heart, peripheral blood lymphocytes, liver, pancreas, spleen, thymus, prostate, ovary, uterus, placenta, testis, esophagus, stomach and throughout the intestinal tract; not detectable in brain.

研究领域

· Cellular Processes > Cell growth and death > p53 signaling pathway.   (View pathway)

· Cellular Processes > Cell growth and death > Apoptosis.   (View pathway)

· Cellular Processes > Cell growth and death > Necroptosis.   (View pathway)

· Environmental Information Processing > Signaling molecules and interaction > Cytokine-cytokine receptor interaction.   (View pathway)

· Human Diseases > Infectious diseases: Viral > Measles.

· Human Diseases > Infectious diseases: Viral > Influenza A.

· Organismal Systems > Immune system > Natural killer cell mediated cytotoxicity.   (View pathway)

文献引用

1). Akkermansia muciniphila Aspartic Protease Amuc_1434* Inhibits Human Colorectal Cancer LS174T Cell Viability via TRAIL-Mediated Apoptosis Pathway. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020 (PubMed: 32403433) [IF=5.6]

Application: WB    Species: human    Sample: LS174T cells

Figure 5. | Amuc_1434* mediated the activation of the apoptosis pathway in LS174T cells. (A) The expression of death receptor 4 (DR4), death receptor 5 (DR5), cysteinyl aspartate specific proteinase 8(caspase 8) and cysteinyl aspartate specific proteinase 3 (caspase 3) induced by Amuc_1434* in LS174T cells was dependent on tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). (a) LS174T cells were treated with 8 and 64 µg/mL Amuc_1434* for 24 h, respectively. The cell lysates were analyzed by Western blot.
2). Bisimidazolium Salt Glycosyltransferase Inhibitors Suppress Hepatocellular Carcinoma Progression In Vitro and In Vivo. Pharmaceuticals, 2022 (PubMed: 35745636) [IF=4.6]

Application: WB    Species: Human    Sample: HepG2 cells

Figure 5 C20/C22 increased the sensitivity of HepG2 cells to TRAIL-induced apoptosis. (A,B) WB analysis of the expression of DR4 and 5 in HepG2 cells that were treated with 2 μM C20/C22 for 0, 6, 12, and 24 h. ImageJ software was used to calculate the gray value (n = 3). (C,D) The immunofluorescence assays used to determine the intracellular and cell surface distribution of DR4/5. (E,F) Annexin V/PI double staining was used to detect the apoptotic cells after the indicated treatments (n = 3). (G,H) WB analysis of the expression of Fas in HepG2 cells treated with C20/C22 for 0, 6, 12, and 24 h. (I) The immunofluorescence assays used to determine the intracellular and cell surface distribution of Fas. (J,K) Flow cytometry analysis of the apoptotic cells after the indicated treatments (n = 3). Scale bars, 10 µm. Data shown correspond to the mean ± SD of three independent experiments. The p-value for all datasets was analyzed by one-way ANOVA followed by Tukey’s test using GraphPad Prism version 8.00, except the data in (B) whose p-value was analyzed by nonparametric Dunnett’s test using GraphPad Prism version 8.00. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, and ns nonsignificant vs. 0 h/control group.

Application: IF/ICC    Species: Human    Sample: HepG2 cells

Figure 5 C20/C22 increased the sensitivity of HepG2 cells to TRAIL-induced apoptosis. (A,B) WB analysis of the expression of DR4 and 5 in HepG2 cells that were treated with 2 μM C20/C22 for 0, 6, 12, and 24 h. ImageJ software was used to calculate the gray value (n = 3). (C,D) The immunofluorescence assays used to determine the intracellular and cell surface distribution of DR4/5. (E,F) Annexin V/PI double staining was used to detect the apoptotic cells after the indicated treatments (n = 3). (G,H) WB analysis of the expression of Fas in HepG2 cells treated with C20/C22 for 0, 6, 12, and 24 h. (I) The immunofluorescence assays used to determine the intracellular and cell surface distribution of Fas. (J,K) Flow cytometry analysis of the apoptotic cells after the indicated treatments (n = 3). Scale bars, 10 µm. Data shown correspond to the mean ± SD of three independent experiments. The p-value for all datasets was analyzed by one-way ANOVA followed by Tukey’s test using GraphPad Prism version 8.00, except the data in (B) whose p-value was analyzed by nonparametric Dunnett’s test using GraphPad Prism version 8.00. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, and ns nonsignificant vs. 0 h/control group.
3). Sphingomyelin synthase 2 overexpression promotes cisplatin-induced apoptosis of HepG2 cells. Oncology Letters, 2018 (PubMed: 29375716) [IF=2.5]

Application: WB    Species: human    Sample: HepG2 cells

Figure 2.| Expression of DR4, DR5, cleaved caspase‑3 and c‑Myc in HepG2 cells. (A) The protein expression of DR4, DR5, cleaved caspase‑3 and c‑Myc was investigated using western blotting. Quantification and statistical analysis was performed on (B) DR4, (C) DR5, (D) cleaved caspase‑3 and (E) c‑Myc. n=3, *P<0.05, **P<0.001 vs. control group; #P<0.05, ##P<0.001 vs. control + DDP group. DR. death receptor; DDP, cisplatin; SMS2, sphyngomyelin synthase 2; c‑Myc, avian myelocytomatosis viral oncogene homolog.

限制条款

产品的规格、报价、验证数据请以官网为准，官网链接：www.affbiotech.com | www.affbiotech.cn（简体中文）| www.affbiotech.jp（日本語）

产品的数据信息为Affinity所有，未经授权不得收集Affinity官网数据或资料用于商业用途，对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整，如您已订购该产品，请以订购时随货说明书为准，否则请以官网内容为准，官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时，请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。 

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.